| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over |
|
Medicine details |
|
| Medicine name | Brexucabtagene autoleucel (Tecartus®) |
| Formulation | intravenous infusion |
| Reference number | 4162 |
| Indication | For the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) |
| Company | Gilead Sciences Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/04/2023 |
| NICE guidance | |